Latest / DDReg Knowledge Capsule / Realities of EAEU Pharmaceutical Registration

Transcript

Realities of EAEU Pharmaceutical Registration · DDReg Knowledge Capsule

• 0:00
  Speaker 1: Welcome to DD Reg Knowledge Capsule. I want you to
• 0:03
  Speaker 1: imagine for a second that you've just finalized a groundbreaking
• 0:08
  Speaker 1: new medicine.
• 0:09
  Speaker 2: Oh, the ultimate dream scenario for any pharma company, right?
• 0:12
  Speaker 1: Right, exactly. You have, you know, spent years in R
• 0:16
  Speaker 1: & D. You've navigated all the clinical trials. And now
• 0:20
  Speaker 1: you are strategizing the big commercial payoff.
• 0:22
  Speaker 2: The finish line is in sight.
• 0:24
  Speaker 1: Yeah. And you want to launch this product across an
• 0:27
  Speaker 1: entire region of five countries all at once. So you're
• 0:29
  Speaker 1: looking at the Eurasian Economic Union, and you hear about
• 0:33
  Speaker 1: this regulatory pathway called the unified procedure.
• 0:36
  Speaker 2: Which sounds fantastic on paper.
• 0:38
  Speaker 1: It really does. Your immediate thought, you know, as a
• 0:41
  Speaker 1: pharmaceutical executive is probably, oh, great, one unified form to
• 0:45
  Speaker 1: fill out, one centralized approval, and seamless market access across
• 0:49
  Speaker 1: five sovereign borders.
• 0:51
  Speaker 2: Yeah, I mean, the industry absolutely loves the concept of
• 0:54
  Speaker 2: a single streamlined pathway, especially when you're looking at emerging
• 0:57
  Speaker 2: markets with really complex regulatory landscapes.
• 1:01
  Speaker 1: But then the reality of international bureaucracy hits you. And
• 1:05
  Speaker 1: you realize the word unified is doing an incredible amount
• 1:09
  Speaker 1: of heavy lifting here.
• 1:10
  Speaker 2: Oh, it's doing the most heavy lifting. We see the
• 1:13
  Speaker 2: word unified and we just, we project all our own
• 1:16
  Speaker 2: expectations onto it. But a unified procedural framework does not
• 1:21
  Speaker 2: magically erase national borders. And it definitely doesn't override the
• 1:25
  Speaker 2: sovereign health care requirements of individual nations.
• 1:28
  Speaker 1: Which brings us to the source for this deep dive.
• 1:30
  Speaker 1: It's an incredibly insightful guide provided by DDREG, and it's
• 1:34
  Speaker 1: titled EAEU Pharmaceutical Registration, What's Not Unified Procedure?
• 1:39
  Speaker 2: It's a great read.
• 1:40
  Speaker 1: Very sobering, if you're planning a launch.
• 1:42
  Speaker 2: Definitely sobering.
• 1:44
  Speaker 1: So our mission today is to guide you through that
• 1:47
  Speaker 1: massive gap, the gap between the promise of a unified
• 1:50
  Speaker 1: regulatory pathway and the highly fragmented country-specific realities on the
• 1:56
  Speaker 1: ground in the Eurasian Economic Union.
• 1:58
  Speaker 2: Because that gap, well, that gap between expectation and execution
• 2:01
  Speaker 2: is where international manufacturers face their most expensive delays.
• 2:05
  Speaker 1: Yeah. We are mapping out where this harmonized system actually works.
• 2:10
  Speaker 1: And more importantly, exploring the mechanisms behind the roadblocks. Because
• 2:16
  Speaker 1: assuming too much uniformity could just, you know, completely derail
• 2:20
  Speaker 1: a multi-state product launch.
• 2:21
  Speaker 2: Absolutely. The EAEU represents a massive commercial opportunity, right? But
• 2:26
  Speaker 2: capturing that value requires a deep understanding of the underlying architecture.
• 2:31
  Speaker 1: So let's define that playing field first. We are talking
• 2:33
  Speaker 1: about five member states. We've got Russia, Belarus, Kazakhstan, Armenia,
• 2:38
  Speaker 1: and Kyrgyzstan.
• 2:39
  Speaker 2: Right. Those five.
• 2:41
  Speaker 1: And overlying those five countries is the Eurasian Economic Commission,
• 2:44
  Speaker 1: or the EEC. They act as the supranational body, kind
• 2:48
  Speaker 1: of developing the common rules for the union.
• 2:50
  Speaker 2: Exactly. They set the baseline.
• 2:51
  Speaker 1: But each individual state still fiercely guards its own national
• 2:55
  Speaker 1: competent authorities, agencies like Russia's Ministry of Health or Kazakhstan's
• 3:00
  Speaker 1: National Center for Expertise of Medicines.
• 3:02
  Speaker 2: Yeah, the local heavyweights. Right.
• 3:04
  Speaker 1: OK, let's unpack this, because this sounds a bit like
• 3:07
  Speaker 1: a group project in school. You have one common rubric,
• 3:11
  Speaker 1: which is the Eurasian Economic Commission, but you still have
• 3:14
  Speaker 1: five different teachers grading you individually based on their own
• 3:17
  Speaker 1: national authorities.
• 3:18
  Speaker 2: That is a remarkably accurate way to look at it.
• 3:21
  Speaker 2: You have to remember health care is inextricably linked to
• 3:24
  Speaker 2: national sovereignty. It's tied to local economic budgets, you know,
• 3:28
  Speaker 2: historical infrastructure.
• 3:30
  Speaker 1: Which vary wildly between these countries, I imagine.
• 3:33
  Speaker 2: Vastly. This dual architecture exists because these five countries have
• 3:37
  Speaker 2: completely different population sizes, local epidemiological needs, and domestic manufacturing capabilities.
• 3:44
  Speaker 1: So they can't just have a one-size-fits-all approach.
• 3:47
  Speaker 2: Right. The EEA establishes the baseline rules of the game,
• 3:51
  Speaker 2: things like standard dossier registration formats, basic examination standards, and
• 3:56
  Speaker 2: good manufacturing practices.
• 3:58
  Speaker 1: But the actual approval?
• 4:00
  Speaker 2: The day-to-day regulation, the actual scientific evaluation of a drug's safety,
• 4:06
  Speaker 2: and the ultimate decision to let a product into a
• 4:08
  Speaker 2: specific market, that firmly remains at the national level.
• 4:12
  Speaker 1: So they basically believe that having multiple jurisdictions complicates things.
• 4:17
  Speaker 1: but ultimately makes it safer.
• 4:19
  Speaker 2: Exactly. It enriches the safety and efficacy standards for the
• 4:23
  Speaker 2: entire region when multiple distinct agencies are looking at the data.
• 4:26
  Speaker 1: Okay, so because of that architecture, if you're a pharmaceutical
• 4:30
  Speaker 1: company entering this market, you face a fundamental strategic choice
• 4:35
  Speaker 1: right out of the gate.
• 4:36
  Speaker 2: A huge choice.
• 4:37
  Speaker 1: You can pursue this unified procedure, which is the multi-state
• 4:40
  Speaker 1: process we are dissecting today, or you can bypass the
• 4:44
  Speaker 1: regional framework entirely And just go for a purely national
• 4:47
  Speaker 1: pathway in one specific country.
• 4:49
  Speaker 2: Assuming that specific country's national laws still allow for it.
• 4:53
  Speaker 1: Yes.
• 4:54
  Speaker 2: Right.
• 4:55
  Speaker 1: So for anyone listening who is currently mapping out a
• 4:57
  Speaker 1: commercial timeline, understanding the mechanics of that choice is critical.
• 5:02
  Speaker 1: Because if you pick the unified procedure just because you
• 5:04
  Speaker 1: misunderstood the extent of the harmonization.
• 5:06
  Speaker 2: Oh, it's a nightmare. You can set a launchback by months,
• 5:09
  Speaker 2: even years. Wow.
• 5:10
  Speaker 1: Just scrambling to backfill missing national documentation.
• 5:13
  Speaker 2: Exactly.
• 5:14
  Speaker 1: Exactly.
• 5:14
  Speaker 2: The unified procedure provides a coordinated route for dossier submission.
• 5:19
  Speaker 2: It gives the member states a timeline to talk to
• 5:21
  Speaker 2: each other.
• 5:22
  Speaker 1: But it's not a blanket approval.
• 5:24
  Speaker 2: It is not, under any circumstances, an automatic, unconditional approval
• 5:28
  Speaker 2: that forces one country to just blindly accept the scientific
• 5:32
  Speaker 2: conclusions of another.
• 5:33
  Speaker 1: Okay, so let's decode how this procedure actually works in practice.
• 5:37
  Speaker 1: And let's look at the EAEU CTD, the Common Technical Document.
• 5:41
  Speaker 1: It uses a standard five-module structure, right?
• 5:44
  Speaker 2: Yeah. Standard five modules.
• 5:45
  Speaker 1: Module one handles all the administrative data. Module two has
• 5:49
  Speaker 1: the scientific summaries. Module three covers quality and CMC. Module
• 5:53
  Speaker 1: four is non-clinical. And module five is clinical study reports.
• 5:58
  Speaker 2: A very familiar format for most global regulatory teams. Right.
• 6:02
  Speaker 1: And under this unified procedure, you select a reference state
• 6:05
  Speaker 1: to take the lead on the review, while the other
• 6:07
  Speaker 1: countries you want to enter Act as concerned states.
• 6:10
  Speaker 2: Exactly. The reference member state takes on the heavy burden
• 6:13
  Speaker 2: of the primary scientific assessment.
• 6:15
  Speaker 1: Like the main reviewer.
• 6:16
  Speaker 2: Right. They evaluate all the raw clinical and manufacturing data
• 6:19
  Speaker 2: to ensure the drug is actually safe and effective.
• 6:22
  Speaker 1: And the concerned states, what are they doing during this time?
• 6:24
  Speaker 2: Well, they participate by reviewing the assessment report generated by
• 6:27
  Speaker 2: the reference state. But their primary focus really shifts to
• 6:30
  Speaker 2: evaluating how the product addresses their own specific localized requirements.
• 6:35
  Speaker 1: OK, wait, isn't this just the European Union's mutual recognition
• 6:38
  Speaker 1: procedure with a different acronym? Like if I have an
• 6:41
  Speaker 1: EU dossier, can't I just copy paste it for the EAEU?
• 6:46
  Speaker 2: If we connect this to the bigger picture, it's easy
• 6:48
  Speaker 2: to see why so many foreign companies make that exact assumption.
• 6:51
  Speaker 2: The terminology is almost identical. Right.
• 6:54
  Speaker 1: Reference state, concern state.
• 6:56
  Speaker 2: It sounds like the EU. It sounds like it, but
• 6:59
  Speaker 2: the foundational legal frameworks are completely distinct. In the European Union,
• 7:03
  Speaker 2: the mutual recognition procedure is fundamentally reliant on a drug
• 7:06
  Speaker 2: already possessing a finalized marketing authorization in one member state.
• 7:11
  Speaker 1: Oh, so you already have a fully approved product.
• 7:13
  Speaker 2: Right. You are taking a fully approved, nationally recognized product
• 7:18
  Speaker 2: and asking the other 26 EU states to mutually recognize
• 7:21
  Speaker 2: that existing approval.
• 7:24
  Speaker 1: But the EAEU unified procedure isn't like that.
• 7:26
  Speaker 2: Not at all. With the EAEU, you are applying for
• 7:30
  Speaker 2: a coordinated multi-state registration from scratch. You are not relying
• 7:34
  Speaker 2: on a prior national authorization to force recognition.
• 7:38
  Speaker 1: Okay. So if we think of this like building a
• 7:40
  Speaker 1: multi-state housing development, the EAEU reference state is acting as
• 7:44
  Speaker 1: your lead structural engineer.
• 7:46
  Speaker 2: I like this analogy. Yeah.
• 7:47
  Speaker 1: They check the scientific foundation and the clinical plumbing, you know,
• 7:50
  Speaker 1: to make sure the core drug is actually sound. But
• 7:53
  Speaker 1: the concerned states act more like local zoning boards.
• 7:57
  Speaker 2: Exactly. They trust the structural engineer's math on the building's safety.
• 8:02
  Speaker 1: But they are combing through your application to make sure
• 8:04
  Speaker 1: the paint colors, the localized labeling, and the neighborhood-specific safety
• 8:08
  Speaker 1: rules meet their own strict local codes.
• 8:11
  Speaker 2: That captures the dynamic perfectly.
• 8:13
  Speaker 1: Thank you.
• 8:14
  Speaker 2: And that is exactly why taking a standard European or U.S. submission,
• 8:18
  Speaker 2: slapping a translated cover letter on it, and submitting it
• 8:21
  Speaker 2: to the EAEU leads to immediate rejection.
• 8:23
  Speaker 1: They just toss it out.
• 8:25
  Speaker 2: Completely. Even though both regions utilize a five-module CTD format,
• 8:29
  Speaker 2: the EAEU demands its own highly specific administrative requirements in
• 8:32
  Speaker 2: Module 1.
• 8:33
  Speaker 1: And localized data formats, I assume. Oh, yeah.
• 8:36
  Speaker 2: Distinct localized data presentation formats and region-specific risk management plans
• 8:41
  Speaker 2: that a standard European dossier simply does not contain.
• 8:45
  Speaker 1: Which brings us to the core reality of our source
• 8:48
  Speaker 1: material today. We really need to explore the specific traps
• 8:52
  Speaker 1: where the unified label lulls companies into a false sense
• 8:55
  Speaker 1: of security.
• 8:56
  Speaker 2: The traps are where the budgets really get blown. Right.
• 8:59
  Speaker 1: So let's look at the critical components of launching a
• 9:02
  Speaker 1: commercial drug that are absolutely not unified, starting with the
• 9:06
  Speaker 1: bottom line, which is pricing.
• 9:08
  Speaker 2: Pricing. Right. Always a headache. Right.
• 9:11
  Speaker 1: You can secure a unified marketing authorization allowing you to
• 9:14
  Speaker 1: sell your drug in all five countries. But that authorization
• 9:17
  Speaker 1: dictates absolutely nothing about what you can actually charge for it.
• 9:21
  Speaker 2: Because health system decisions, formulary access, and pricing structures are
• 9:25
  Speaker 2: stubbornly national, they are tied directly to individual sovereign health
• 9:30
  Speaker 2: care budgets.
• 9:32
  Speaker 1: So the EAEU has no single pricing or reimbursement system
• 9:36
  Speaker 1: at all?
• 9:37
  Speaker 2: None. In Russia, for example, if your product is classified
• 9:40
  Speaker 2: under the VED category, vital and essential drugs, you are
• 9:44
  Speaker 2: required to undergo a highly complex localized price registration process.
• 9:50
  Speaker 1: And that's totally separate from the marketing approval.
• 9:53
  Speaker 2: Completely separate. It's a distinct bureaucratic workflow that you really
• 9:57
  Speaker 2: must manage in parallel to your marketing authorization.
• 10:00
  Speaker 1: What happens if a company just waits, like they wait
• 10:03
  Speaker 1: until their drug is approved to even start the pricing negotiations?
• 10:07
  Speaker 2: If they wait, they will face massive, entirely avoidable launch
• 10:10
  Speaker 2: delays in their most important market. You just can't afford
• 10:13
  Speaker 2: to do them sequentially.
• 10:14
  Speaker 1: Right. And the lack of unification extends deeply into the
• 10:17
  Speaker 1: packaging and the paperwork itself. Our DD RegSource highlights the
• 10:21
  Speaker 1: huge linguistic fragmentation across these five borders.
• 10:25
  Speaker 2: It is a massive hurdle. The EAEU provides harmonized guidelines
• 10:30
  Speaker 2: for what broad categories of information need to be on
• 10:33
  Speaker 2: a label, but the execution of that label is fiercely national.
• 10:37
  Speaker 1: Yeah, you need Russian for Russia, Belarus, and Kazakhstan. You
• 10:41
  Speaker 1: need Armenian for Armenia, and you need Kyrgyz and or
• 10:45
  Speaker 1: Russian for Kyrgyzstan.
• 10:47
  Speaker 2: And the complexity goes far beyond simply swapping out the vocabulary.
• 10:51
  Speaker 1: How so?
• 10:51
  Speaker 2: Well, individual member states enforce variations in how specific regulatory
• 10:56
  Speaker 2: statements must be phrased, or exactly how storage conditions are
• 11:00
  Speaker 2: formatted on the box.
• 11:01
  Speaker 1: Oh, so it's not just the language, it's the actual
• 11:03
  Speaker 1: layout and phrasing required by law. Yes.
• 11:07
  Speaker 2: They even mandate the inclusion of local regulatory contact information
• 11:11
  Speaker 2: on the physical secondary packaging.
• 11:12
  Speaker 1: Okay, here's where it gets really interesting. Because the need
• 11:16
  Speaker 1: for hyper-accurate local language doesn't just stop with a cardboard box.
• 11:19
  Speaker 1: The dossier itself requires intense, localized translation.
• 11:24
  Speaker 2: We're talking about highly complex, life-or-death scientific information.
• 11:28
  Speaker 1: Exactly. You can't just run this through Google Translate and
• 11:30
  Speaker 1: hope for the best. A manufacturer cannot rely on machine
• 11:34
  Speaker 1: translation for things like Module 2 safety summaries or the
• 11:38
  Speaker 1: Module 1 administrative risk management plans.
• 11:40
  Speaker 2: No, absolutely not. Relying on automated translation for scientific dossiers
• 11:45
  Speaker 2: generates completely avoidable deficiencies.
• 11:48
  Speaker 1: Because the reviewers catch it immediately.
• 11:50
  Speaker 2: Right. Regulatory reviewers in these national agencies are evaluating the
• 11:54
  Speaker 2: precise medical terminology used to describe adverse events and pharmacokinetic profiles.
• 12:00
  Speaker 1: So if a word is slightly off.
• 12:02
  Speaker 2: If the translation is imprecise, the scientific validity of the
• 12:05
  Speaker 2: entire application is called into question. Professional, regulatory-grade translation is mandatory.
• 12:12
  Speaker 1: Like by subject matter experts who actually understand the specific
• 12:16
  Speaker 1: medical dialects of each member state.
• 12:17
  Speaker 2: Exactly. It is an absolute operational necessity, not an optional expense.
• 12:22
  Speaker 1: Let's follow that thread, because if a patient in one
• 12:25
  Speaker 1: of these countries reads that localized label, takes the medicine,
• 12:28
  Speaker 1: and suffers an adverse reaction, we immediately hit the biggest
• 12:32
  Speaker 1: and most dangerous trap of all.
• 12:34
  Speaker 2: Pharmacovigilance.
• 12:35
  Speaker 1: Pharmacovigilance. the ongoing monitoring of a drug's safety once it's
• 12:39
  Speaker 1: on the market. Now, the source material points out that
• 12:42
  Speaker 1: the EAEU does have common good pharmacovigilance practice rules, the EAEU-GVP.
• 12:48
  Speaker 2: Right. So there is a shared baseline standard for safety
• 12:51
  Speaker 2: monitoring across the board.
• 12:53
  Speaker 1: But the actual reporting obligations for the marketing authorization holder
• 12:57
  Speaker 1: seem almost intractably fragmented.
• 13:01
  Speaker 2: This is where the illusion of a unified system creates
• 13:04
  Speaker 2: severe legal and compliance vulnerabilities.
• 13:07
  Speaker 1: Because of how the data is handled.
• 13:09
  Speaker 2: Yeah. The EAEU-GVP provides a harmonized methodology for how to
• 13:14
  Speaker 2: collect and analyze safety data. However, the operational execution, where, when,
• 13:19
  Speaker 2: and how you report that data remains strictly national.
• 13:22
  Speaker 1: So Russia, for instance.
• 13:24
  Speaker 2: Right. Russia requires all adverse events occurring on its soil
• 13:27
  Speaker 2: to be reported directly to their specific national database.
• 13:31
  Speaker 1: Which is managed by Rosdrovnatsor. Did I say that right?
• 13:35
  Speaker 2: You did. Rozhdravnazor. It's the formidable Russian federal health care
• 13:40
  Speaker 2: surveillance agency.
• 13:41
  Speaker 1: So a company is basically forced to manage parallel, unsynced databases.
• 13:45
  Speaker 1: If an adverse event happens in Russia, you report it
• 13:48
  Speaker 1: to Rozhdravnazor. But that report doesn't automatically propagate to the
• 13:52
  Speaker 1: health authorities in Kazakhstan or Armenia.
• 13:55
  Speaker 2: It does not propagate at all. The reporting timelines, the
• 13:58
  Speaker 2: specific XML formats for individual case safety reports, And the
• 14:02
  Speaker 2: schedules for submitting periodic safety update reports differ significantly between
• 14:06
  Speaker 2: Russia and the other member states. Wow.
• 14:09
  Speaker 1: So the legal responsibility falls squarely on the pharmaceutical company
• 14:12
  Speaker 1: to maintain this parallel reporting compliance in each member state independently.
• 14:16
  Speaker 2: Yes. There is no central unified portal that automatically satisfies
• 14:20
  Speaker 2: the obligations of all five countries simultaneously.
• 14:23
  Speaker 1: That highlights a chilling mechanical reality for any compliance officer
• 14:26
  Speaker 1: listening right now. If your company assumes that an EAEU
• 14:30
  Speaker 1: registration handles all your pharmacovigilance obligations automatically, you are.
• 14:34
  Speaker 2: Going to find yourself in a state of legal noncompliance
• 14:36
  Speaker 2: on day one, literally the very first post-registration reporting cycle.
• 14:41
  Speaker 1: You cannot figure out local safety reporting after the drug
• 14:44
  Speaker 1: is approved.
• 14:44
  Speaker 2: No. You have to build the local infrastructure, hire the
• 14:47
  Speaker 2: local safety personnel, and integrate with agencies like Ruzdrav, Nadzor
• 14:52
  Speaker 2: way before the product ever reaches a patient's hands.
• 14:55
  Speaker 1: The local safety nets have to be fully operational and
• 14:57
  Speaker 1: stress tested prior to launch.
• 14:59
  Speaker 2: Because failing to do so doesn't just risk fines. It
• 15:02
  Speaker 2: risks the immediate suspension of the marketing authorization you just
• 15:06
  Speaker 2: spent years and millions of dollars securing.
• 15:09
  Speaker 1: Since pricing, translation, and pharmacovigilance all ultimately hinge on the
• 15:13
  Speaker 1: demands of national authorities, we really have to look closely
• 15:17
  Speaker 1: at the dominant player in this union.
• 15:19
  Speaker 2: Russia. Russia.
• 15:21
  Speaker 1: For most global pharmaceutical companies, the entire commercial viability of
• 15:25
  Speaker 1: the Eurasian Economic Union hinges on access to Russia. It
• 15:29
  Speaker 1: is the prize that justifies the immense administrative burden of
• 15:32
  Speaker 1: this whole unified procedure.
• 15:34
  Speaker 2: Absolutely. And Russia has historically utilized its market weight to
• 15:38
  Speaker 2: demand very specific clinical data.
• 15:41
  Speaker 1: Like local trials.
• 15:42
  Speaker 2: Right. Historically, the Russian Ministry of Health created a massive
• 15:47
  Speaker 2: bottleneck for international manufacturers. They demanded that foreign companies conduct
• 15:51
  Speaker 2: localized phase three clinical trials on Russian soil before they
• 15:55
  Speaker 2: would even review an innovative medicine for registration.
• 15:58
  Speaker 1: Which is an incredibly costly and time consuming barrier to entry.
• 16:03
  Speaker 2: Massive barrier.
• 16:04
  Speaker 1: But the source notes a pretty significant pivot in recent years, right?
• 16:07
  Speaker 1: Russia has shifted toward a more risk based approach to
• 16:10
  Speaker 1: local study requirements.
• 16:12
  Speaker 2: Yeah, they recognized that demanding redundant phase three trials was
• 16:15
  Speaker 2: delaying Russian patients' access to innovative, life-saving therapies.
• 16:20
  Speaker 1: So today, if a medicine has been rigorously vetted and
• 16:22
  Speaker 1: approved by major ICH member agencies, full-scale local phase three
• 16:26
  Speaker 1: trials are rarely demanded up front.
• 16:29
  Speaker 2: And that shift is monumental for global development strategies.
• 16:32
  Speaker 1: Just to clarify, the ICH is the International Council for Harmonization, right?
• 16:37
  Speaker 2: Yes, the International Council for Harmonization of Technical Requirements for
• 16:41
  Speaker 2: Pharmaceuticals for Human Use. Its primary regulatory members include the U.S. FDA,
• 16:45
  Speaker 2: the European Medicines Agency, and Japan's PMDA.
• 16:49
  Speaker 1: Okay, so the big players. Right.
• 16:51
  Speaker 2: Because these agencies demand the highest global standards for clinical
• 16:54
  Speaker 2: trial design and data integrity, the Russian Ministry of Health
• 16:58
  Speaker 2: now places significant weight on their approvals.
• 17:00
  Speaker 1: So if your drug carries an FDA or EMA approval
• 17:04
  Speaker 1: supported by robust... multinational phase three data, Russia is far
• 17:08
  Speaker 1: more willing to accept that clinical package.
• 17:10
  Speaker 2: Far more willing, yes.
• 17:12
  Speaker 1: But a manufacturer still has to explain why data gathered in, say,
• 17:16
  Speaker 1: North America or Western Europe is relevant to the Russian population.
• 17:20
  Speaker 1: You can't just hand over the FDA approval and expect
• 17:22
  Speaker 1: a rubber stamp.
• 17:23
  Speaker 2: No, definitely not a rubber stamp.
• 17:25
  Speaker 1: You have to provide what the regulations call rigorous scientific
• 17:28
  Speaker 1: justification to extrapolate that foreign data. How does a company
• 17:32
  Speaker 1: actually do that if they had zero Russian patients in
• 17:35
  Speaker 1: their global trials?
• 17:37
  Speaker 2: Well, providing that justification requires a deep dive into pharmacogenomics
• 17:41
  Speaker 2: and epidemiology. The applicant must scientifically demonstrate that the disease pathology,
• 17:47
  Speaker 2: the mechanism of action of the drug, and the genetic
• 17:50
  Speaker 2: markers of the studied population do not significantly differ from
• 17:53
  Speaker 2: the ethnic and demographic makeup of the Russian population.
• 17:57
  Speaker 1: Wow, so you are literally proving that the drug will
• 18:00
  Speaker 1: metabolize and perform identically in a different demographic.
• 18:03
  Speaker 2: Exactly. And if the Russian regulators are not entirely convinced
• 18:06
  Speaker 2: by that extrapolation, they may still grant the initial authorization,
• 18:10
  Speaker 2: but they will attach a strict post-registration condition.
• 18:14
  Speaker 1: Like demanding localized safety and effectiveness studies in Russian patients
• 18:19
  Speaker 1: immediately after the drug hits the market.
• 18:20
  Speaker 2: Precisely.
• 18:22
  Speaker 1: Which brings us to the timelines for getting that authorization
• 18:25
  Speaker 1: in the first place. The official on-paper target for the
• 18:28
  Speaker 1: unified procedure is is 160 working days from the moment
• 18:32
  Speaker 1: of acceptance to a final decision.
• 18:34
  Speaker 2: On paper, sure.
• 18:36
  Speaker 1: But our DDReg source throws a massive bucket of cold
• 18:39
  Speaker 1: water on that metric. It notes that the reality is
• 18:41
  Speaker 1: frequently 12 to 24 months. What is happening mechanically during
• 18:46
  Speaker 1: that review that turns a 160-day target into a two-year reality?
• 18:51
  Speaker 2: The delay is really driven by the depth of the
• 18:53
  Speaker 2: substantive review conducted by Russia's Center for Expertise of Medicinal Products.
• 18:57
  Speaker 2: They're known as the FEMBEC.
• 18:59
  Speaker 1: So the 160-day timeline assumes a flawless dossier that generates
• 19:04
  Speaker 1: absolutely no questions from the FEMBA.
• 19:06
  Speaker 2: Exactly, which never happens. In reality, the FEMBA conducts incredibly
• 19:11
  Speaker 2: aggressive evaluations of the chemistry, manufacturing, and controls data, the CMC.
• 19:15
  Speaker 1: What kind of questions are they asking?
• 19:17
  Speaker 2: They will issue detailed queries regarding local manufacturing controls, specific
• 19:22
  Speaker 2: impurity thresholds that might differ slightly from the European pharmacopoeia,
• 19:27
  Speaker 2: Or they might request further clarification on the clinical extrapolation
• 19:30
  Speaker 2: we just discussed.
• 19:31
  Speaker 1: And each set of questions stops the regulatory clock, I assume?
• 19:35
  Speaker 2: It completely stops the clock. The applicant has to compile
• 19:38
  Speaker 2: the new data, get it professionally translated, and submit it.
• 19:41
  Speaker 2: This triggers multiple sequential review cycles that easily push the
• 19:45
  Speaker 2: total elapsed time past that 12- to 24-month mark. Okay.
• 19:49
  Speaker 1: Luke? at all of this, the complex translation requirements, the
• 19:53
  Speaker 1: parallel pricing workflows, the fragmented safety databases, and a review
• 19:57
  Speaker 1: process heavily dictated by Russia's VEMS.
• 20:00
  Speaker 2: It's a lot to take in.
• 20:01
  Speaker 1: It begs a strategic question. If I'm a manufacturer looking
• 20:04
  Speaker 1: at my global footprint and Russia is my only immediate
• 20:08
  Speaker 1: target market within this region, Why would I even bother
• 20:11
  Speaker 1: with the unified procedure? Shouldn't I just file nationally in
• 20:15
  Speaker 1: Russia under their specific federal laws and bypass the coordination
• 20:19
  Speaker 1: headache of the other four countries?
• 20:20
  Speaker 2: This raises an important question, and it's the most vital
• 20:23
  Speaker 2: strategic calculus a regulatory affairs team must perform.
• 20:27
  Speaker 1: So it's a valid option?
• 20:29
  Speaker 2: Very valid. If simultaneous multi-state launch is not the immediate priority,
• 20:33
  Speaker 2: the Russian National Pathway, operating under federal law number 61-FZ...
• 20:38
  Speaker 2: is frequently the more pragmatic choice.
• 20:41
  Speaker 1: Because it just cuts out the noise.
• 20:43
  Speaker 2: Right. It eliminates the need to coordinate with concerned states,
• 20:47
  Speaker 2: removes the requirement to translate the dossier into languages other
• 20:50
  Speaker 2: than Russian, and gives the manufacturer much tighter control over
• 20:54
  Speaker 2: the review timelines with a single agency.
• 20:57
  Speaker 1: So the unified procedure provides immense value, but only if
• 21:00
  Speaker 1: your commercial strategy genuinely demands multi-state market access from day one. Exactly.
• 21:06
  Speaker 2: It has to align with your actual business goals.
• 21:09
  Speaker 1: We also need to examine a critical regulatory deadline highlighted
• 21:13
  Speaker 1: in the source material that has completely reshaped the landscape
• 21:16
  Speaker 1: for older drugs. December 31st, 2025.
• 21:20
  Speaker 2: Oh, the transition deadline. Right.
• 21:22
  Speaker 1: This was the end of the transition period. What exactly
• 21:25
  Speaker 1: happened mechanically at that deadline for medicines that had been
• 21:28
  Speaker 1: on the market for years?
• 21:29
  Speaker 2: Well, prior to the EAEU framework, every medicine was registered
• 21:34
  Speaker 2: under local national rules with completely different dossier structures. When
• 21:38
  Speaker 2: the unified system launched, regulators provided a grace period for
• 21:42
  Speaker 2: manufacturers to bring those legacy nationally registered dossiers up to
• 21:46
  Speaker 2: the new five-module EAEU CTD standard.
• 21:50
  Speaker 1: And the December 2025 deadline marked the absolute end of
• 21:53
  Speaker 1: that grace period.
• 21:54
  Speaker 2: Yes, the door closed.
• 21:56
  Speaker 1: So companies couldn't just assume their old Russian or Kazakh
• 22:00
  Speaker 1: registrations were safe indefinitely. They had actively performed gap analyses
• 22:04
  Speaker 1: between their decade-old national dossiers and the rigorous new EAEU standards.
• 22:10
  Speaker 2: And submit complex variations to align them, yes.
• 22:13
  Speaker 1: If a company missed that alignment deadline, they aren't just
• 22:16
  Speaker 1: facing paperwork fines, right? They are facing the imminent suspension
• 22:19
  Speaker 1: of their marketing authorizations.
• 22:21
  Speaker 2: Which means immediate supply disruptions and empty pharmacy shelves across
• 22:25
  Speaker 2: the entire region.
• 22:26
  Speaker 1: That is terrifying for a supply chain manager.
• 22:29
  Speaker 2: It is precisely the danger. The regulatory transition period is
• 22:33
  Speaker 2: definitively over. Any manufacturer relying on pre-EAEU national registrations must
• 22:39
  Speaker 2: urgently audit their portfolio product by product.
• 22:42
  Speaker 1: Because if they fail to submit the required alignment dossiers,
• 22:45
  Speaker 1: their legal right to commercialize those products is currently in
• 22:48
  Speaker 1: severe jeopardy.
• 22:49
  Speaker 2: It's a massive compliance risk right now.
• 22:51
  Speaker 1: Okay. So what does this all mean? If we zoom
• 22:54
  Speaker 1: out and synthesize the reality D.D. Rigg has outlined for us,
• 22:58
  Speaker 1: the ultimate takeaway is a total redefinition of the word unified.
• 23:03
  Speaker 2: Without a doubt.
• 23:04
  Speaker 1: In the Eurasian Economic Union, unified means procedural coordination. It
• 23:09
  Speaker 1: absolutely does not mean operational uniformity.
• 23:13
  Speaker 2: That is the perfect distinction. Success in this region relies
• 23:16
  Speaker 2: entirely on understanding the mechanics of that distinction.
• 23:20
  Speaker 1: Right. It means securing professional regulatory grade translation teams before
• 23:25
  Speaker 1: submission because localized precision is mandatory.
• 23:29
  Speaker 2: It means architecting your national pharmacovigilance infrastructure and integrating with
• 23:34
  Speaker 2: databases like Rosdravnadzor before your drug is ever approved.
• 23:39
  Speaker 1: And it requires treating pricing and reimbursement as a completely separate,
• 23:43
  Speaker 1: parallel workflow that is entirely dependent on sovereign health budgets.
• 23:47
  Speaker 2: The unified framework exists to facilitate multi-state entry, but the
• 23:52
  Speaker 2: sovereign responsibilities of the member states remain the ultimate arbiters
• 23:56
  Speaker 2: of commercial success.
• 23:58
  Speaker 1: You are utilizing a coordinated highway, but you must still
• 24:02
  Speaker 1: stop at individual national toll booths.
• 24:05
  Speaker 2: Paying in specific local currencies with localized paperwork and subject
• 24:09
  Speaker 2: to distinct national inspections.
• 24:11
  Speaker 1: As we navigate that friction between the ideal of a
• 24:14
  Speaker 1: regulatory union and the granular reality of national sovereignty, I
• 24:19
  Speaker 1: want to leave you with a final thought to ponder.
• 24:22
  Speaker 1: We have spent this entire deep dive discussing how the
• 24:24
  Speaker 1: EAEU framework is currently straining to manage The harmonization of
• 24:28
  Speaker 1: standard chemical drugs. Right.
• 24:30
  Speaker 2: Struggling with basic translation elements, packaging labels, and localized adverse
• 24:35
  Speaker 2: event reporting.
• 24:36
  Speaker 1: And that struggle is occurring with traditional mass-produced pharmaceuticals. Now,
• 24:40
  Speaker 1: consider the immediate future of medicine.
• 24:43
  Speaker 2: It's a very different landscape coming.
• 24:45
  Speaker 1: We are rapidly entering an era of hyper-personalized treatments. Think
• 24:49
  Speaker 1: of autologous cell therapies, where a specific patient's own cells
• 24:53
  Speaker 1: are harvested, engineered in a lab, and re-infused.
• 24:57
  Speaker 2: Or consider digital therapeutics that rely on constant, real-time biometric
• 25:01
  Speaker 2: feedback transmitted via software.
• 25:03
  Speaker 1: Exactly. These innovations require incredibly rapid, cross-border sharing of highly
• 25:08
  Speaker 1: sensitive patient-specific health data to function safely.
• 25:12
  Speaker 2: They do.
• 25:13
  Speaker 1: If the underlying architecture of the EAEU is currently fragmented
• 25:16
  Speaker 1: over standard safety summaries and parallel pricing databases, how will
• 25:21
  Speaker 1: this regulatory union possibly adapt its rigid national silos to evaluate, monitor,
• 25:28
  Speaker 1: and harmonize the oversight of real-time, hyper-personalized therapies that inherently
• 25:33
  Speaker 1: defy physical borders.
• 25:34
  Speaker 2: It is going to be a massive challenge for the
• 25:37
  Speaker 2: next evolution of international pharmaceutical regulation.
• 25:40
  Speaker 1: Something to really think about as the science outpaces the bureaucracy.
• 25:45
  Speaker 1: Thank you for joining us on this deep dive into
• 25:47
  Speaker 1: the EAEU's unified procedure. Take these insights back to your
• 25:51
  Speaker 1: strategic planning. Keep asking those hard questions. And we will
• 25:54
  Speaker 1: catch you on the next one. Keep exploring.